Ken Griffin 9 Meters Biopharma, Inc. Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.21 - $0.32 $5,839 - $8,898	27,808 New	27,808 $6,000
Q1 2022 May 16, 2022	SELL	$0.52 - $1.0 $37,366 - $71,858	-71,858 Reduced 64.18%	40,108 $24,000
Q4 2021 Feb 14, 2022	SELL	$0.85 - $1.33 $64,967 - $101,654	-76,432 Reduced 40.57%	111,966 $109,000
Q3 2021 Nov 15, 2021	BUY	$1.03 - $1.41 $108,955 - $149,152	105,782 Added 128.04%	188,398 $245,000
Q2 2021 Aug 16, 2021	SELL	$1.04 - $1.5 $144,714 - $208,723	-139,149 Reduced 62.75%	82,616 $90,000
Q1 2021 May 17, 2021	BUY	$0.84 - $2.16 $186,282 - $479,012	221,765 New	221,765 $259,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.